The pro-apoptotic molecule BAD binds BCL-x L or BCL2 and inactivates their survival function. In addition to their anti-apoptotic function, BCL2 and BCL-x L also delay cell cycle entry from quiescence. We found that the BH3-only molecule BAD also exerted a cell cycle eect. BAD expression resulted in failure to cell cycle block in growth arrest conditions. In low serum and in con¯uence, ®broblasts constitutively or inducibly expressing BAD persisted in S phase, continued to incorporate BrdU, and exhibited sustained cyclin E/cdk2 activity. Mutation analysis indicated that the cell cycle eect of BAD was not dependent on its phosphorylation status or subcellular localization, but strictly co-segregated with BCL-x L binding. bclx 7/7 MEFs expressing BAD and bad 7/7 MEFs both arrested in G0/G1 in low serum similar to wild-type controls, suggesting that the ability to overcome the G0/G1 checkpoint resulted from the presence of BAD/BCL-x L heterodimers, rather than the absence of BCL-x L or BAD. These data provide evidence that in addition to regulating apoptosis, the BAD/BCLx L heterodimer has a novel cell cycle function. Oncogene (2001) 20, 4507 ± 4518.
Introduction
BAD is a member of the highly conserved BCL2 family of cell death regulators spanning the evolutionary phyla from C. elegans to mammals (Yang et al., 1995) . BCL2 and its close homolog BCL-x L inhibit apoptosis triggered by a variety of cell death stimuli and are general anti-apoptosis molecules, while other members of the BCL2 family, such as BAX and BAD, are proapoptotic. The BCL2 family proteins variably contain homology domains BH1, BH2, BH3, BH4 (Adams and Cory, 1998; Korsmeyer, 1999 ). An interesting BCL2 subfamily contain only BH3 (Lutz, 2000; Kelekar and Thompson, 1998) , which include BAD, BID, BIK, BIM. These BH3-only molecules appear to function as proximal regulators of BCL2 in speci®c cellular processes. For example, BID functions prominently in the Fas/TNFR induced apoptotic pathway (Luo et al., 1998; Li et al., 1998; Nagata, 1999) . BIM interacts with the dynein light chain LC8 (Puthalakath et al., 1999) , and likely functions in processes involving the cytoskeleton. The recently identi®ed BH3-only molecule Noxa speci®cally mediates p53-induced apoptosis in response to g-irradiation (Oda et al., 2000) .
BAD is a potent BH3-only pro-apoptotic molecule initially isolated as an interacting partner of BCL2, and later found to bind much more strongly to BCL-x L (Yang et al., 1995) . BAD modulates the function of BCL-x L and BCL2 by direct interaction through BH3 (Kelekar et al., 1997; Zha et al., 1997) . The apoptotic activity of BAD is clearly determined by the phosphorylation status of Ser112, Ser136 (Zha et al., 1996; Datta et al., 1997) , and Ser155 (Zhou et al., 2000; Tan et al., 2000; Datta et al., 2000) . Upon withdrawal of survival factors, BAD is rapidly dephosphorylated and targeted to the mitochondria surface where it binds BCL-x L or BCL2, and causes cell death. Reversible phosphorylation of BAD is regulated by kinases, including Akt (Datta et al., 1997) , PKA (Harada et al., 1999) , and p21-activated kinase 1 (Schurmann et al., 2000) , as well as phosphatases, including calcineurin/PP2B , PP1 (Ayllon et al., 2000) , and a PP2A-like enzyme (Chiang et al., 2001) . Changes in BAD phosphorylation occur rapidly in response to apoptotic or survival stimuli mediated by growth factors, consistent with the role of this BH3-only molecule as an upstream apoptosis regulator.
BCL2 expression increases the propensity for tumorigenesis (McDonnell and Korsmeyer, 1991; Linette et al., 1995; Korsmeyer, 1999) . Extensive studies have established that the anti-apoptosis function of BCL2 and BCL-x L plays an important role in oncogenesis. Intriguingly, these cell death regulators also exert cell cycle eects, which are most pronounced in cell cycle entry. Quiescent T cells overexpressing BCL2 or BCL-x L are delayed in activation-induced cell cycle entry, while bcl2 7/7 knockout cells enter S phase more quickly (Linette et al., 1996; Mazel et al., 1996) . In myeloid cells which can be induced to dierentiate, enforced BCL2 hastens exit of cell cycle to G0 and enhances maturation (Vairo et al., 1996) . The ability of BCL2 and BCL-x L to delay G0/G1 to S transition has been well characterized in serum induced cell cycle entry of ®broblasts (O'Reilly et al., 1996; Huang et al., 1997) . In many instances of apoptosis rescued by BCL2, especially those induced by withdrawal of growth factors, the rescued cells are found in G0 or G1. Conversely, cycling cells are more susceptible to apoptotic stimuli than quiescent cells. The cell cycle delay activity of BCL2 can be countered by BAX. T cells from BAX transgenic mice exhibit accelerated entry into S phase, which is associated with faster decline of the cdk inhibitor p27 (Brady et al., 1996) . The cell cycle eects of BCL2 and BCL-x L suggest a relationship between cell cycle control and apoptosis regulation. Modulating cell cycle progression may partially or indirectly contribute to the antiapoptosis activity of BCL2 and BCL-x L . In tumor models, high BCL2 expression is correlated with antiapoptosis and low proliferative rate (Murphy et al., 1999) . In some instances, the anti-mitotic eect of BCL2 is lost with tumor progression (Furth et al., 1999) . Thus, the cell cycle delay function of BCL2 and BCL-x L may also play a role in tumorigenesis.
Since BAD is a strong heterodimerizing partner of BCL-x L , we asked whether BAD also exerts an eect on cell cycle. We found that BAD expression led to a novel cell cycle phenotype. Cells expressing BAD failed to cell cycle arrest despite serum starvation or contact inhibition. The contributions of phosphorylation, subcellular localization, and BCL-x L binding to the cell cycle eect of BAD were investigated. We report that the BAD/BCL-x L heterodimer was responsible for continued S phase entry in growth arrest conditions, and that expression of the BH3-only apoptotic molecule BAD can overcome a G0/G1 arrest signal.
Results

Cells expressing BAD fail to arrest in serum starvation and contact inhibition
To investigate whether BAD aects cell cycle, we constructed stable clones of Rat1 ®broblasts expressing BCL-x L and stable clones expressing BCL-x L and BAD. Anti-BAD immunoprecipitations followed by anti-BCL-x L Western analysis was used to assess BAD/ BCL-x L complex formation ( Figure 1a) . In Rat1 control cells, BCL-x L could be detected by Western blotting from the immunoprecipitate of endogenous BAD, indicating the presence of endogenous BAD/ BCL-x L heterodimers, even though BAD could not be detected due to lower antibody anity. In a BCL-x Loverexpressing Rat1 cell line, more BCL-x L was detected in the BAD immunocomplex. When BAD immunoprecipitate from cells overexpressing both BAD and BCL-x L was immunoblotted for either BAD or BCL-x L , abundant BAD and BCL-x L were detected, indicating that signi®cantly more BAD/BCLx L heterodimers exist in this cell line compared to untransfected control cells (Figure 1a, top panel) . To examine the ratio of free BCL-x L to BAD/BCL-x L heterodimers, BAD immunoprecipitates and the supernatants after BAD immunoprecipitation were Western blotted for BCL-x L (Figure 1a , bottom panel). In BCLx L expressing cells with minimal endogenous BAD, BCL-x L was only detected in the supernatant after BAD immunoprecipitation, as expected ( Figure 1a , bottom panel, lanes 1, 2). In cells expressing both BAD and BCL-x L , the vast majority of BCL-x L was found as heterodimers with BAD, and very little free BCL-x L was detected in the supernatant after BAD immunoprecipitation ( Figure 1a, bottom panel, lanes 3, 4) . Conversely, immunoprecipitations with anti-BCL-x antibody followed by Western blotting of the supernatant for BAD demonstrated that most of BAD was complexed with BCL-x L (data not shown). Thus, these cells contain predominantly BAD/BCL-x L heterodimers and very little free BCL-x L or BAD.
To assay cell cycle kinetics, Rat1 ®broblasts cultured in media containing 10% fetal calf serum (FCS) were induced to arrest in G0/G1 by withdrawing serum from the medium for 48 h or by allowing the cells to remain con¯uent for at least 2 days. Propidium iodide staining and¯ow cytometry analysis showed that while control cells and BCL-x L cells eciently arrested in G0/G1 (2 ± 6% S) after 48 h of low serum or contact inhibition, BCL-x L /BAD cultures had signi®cant fractions (21 and 19%) of cells with DNA content between 2 N and 4 N ( Figure 1b) . Similar results were obtained with several BCL-x L and BAD expressing clones. The presence of cells with S phase DNA content was unlikely to be due to apoptotic eects, since less than 10% apoptosis was detected in these cultures (9.1% in serum starvation and 3.7% in contact inhibition). Rather, the increase in S phase cells suggested continued cell cycle progression despite low serum or culture con¯uence.
To determine whether BCL-x L /BAD cells with S phase DNA content were actively synthesizing DNA, serum starved cultures were pulse labeled with BrdU, and incorporation of BrdU into cellular DNA was measured by FACS analysis (Figure 1c ). BCL-x L / BAD cultures contained a signi®cant proportion of BrdU positive cells with DNA content between 2 N and 4 N (15%) after 48 h of serum starvation. Only background levels of BrdU positivity (0.2 ± 1%) were detected in the vector-transfected and BCL-x L -transfected cells after 48 h of culture in 0.1% FCS. This result suggested that despite a cell cycle arrest stimulus, BAD overexpressing cells continued to traverse S phase.
To con®rm that the persistence of S phase cells resulted from BAD expression, we constructed cell lines expressing inducible BAD in R12 Rat1 ®broblasts using the tetracycline-regulated system. BAD protein expression was eciently induced in cell line R12BAD2-4 when tetracycline was withdrawn from the media (Figure 2 , right panel), and more BCL-x L co-immunoprecipitated with BAD ( Figure 2 , left panel). When both tetracycline and serum were withdrawn for 48 h and cultures were analysed by BrdU/PI staining, induced R12BAD2-4 cells exhibited signi®-cantly more BrdU positive cells compared to uninduced control cells (13% vs 1%) (Figure 2b ). Inducible clones of BAD with a mutation in BH3 (L151A) which abrogates binding to BCL-x L did not exhibit BrdU incorporation above background (data not shown). BrdU/PI data from cells expressing inducible BAD indicated that the observed abnormal S phase progression resulted from BAD expression. Induced cells exhibit more BAD/BCL-x L heterodimers, but uninduced cells which arrest as expected also contain a readily detectable amount of BAD/BCL-x L dimers, suggesting that there may be a threshold level above which BAD/BCL-x L dimers aect cell cycle arrest. The ability of BAD to cause continued cell cycle progression appears to be speci®c for the G0/G1 transition, BCL-x L is localized predominantly to the mitochondria outer membrane. BAD heterodimerizes with BCLx L and co-localizes to the mitochondria. In BAD inducible cells which were not over-expressing BCL-x L , immuno¯uorescence staining showed the majority of BAD to be cytosolic (Figure 2c ). The pro-apoptotic function of BAD has been linked to its mitochondrial localization, but the cell cycle eect of BAD was present in cell line R12BAD2-4 when signi®cant amounts of the protein was cytosolic. The fraction of BAD bound to endogenous BCL-x L or BCL2 would be mitochondrial, and could be the species responsible for the cell cycle eect.
The ability of BAD to cause S phase progression co-segregates with BCL-x L binding Structure-function analysis was performed to determine whether the ability of BAD to cause cell cycle progression is directly linked to its heterodimerization with BCL-x L . Wild-type BAD exists in a phosphorylated and a dephosphorylated form. Only the dephosphorylated form binds BCL-x L and BCL2, while the phosphorylated form is sequestered by 14-3-3 in the cytosol (Zha et al., 1996) . An intact BH3 domain (aa 151 ± 163) of BAD is critical for binding to BCL-x L and BCL2 (Zha et al., 1997; Kelekar et al., 1997) . We infected Rat1BCL-x L cells with recombinant retroviruses containing three mutant BAD constructs. The S112AS136A mutant containing alanine substitutions at both Ser112 and Ser136 phosphorylation sites results in constitutively unphosphorylated BAD which cannot bind 14-3-3, but binds BCL-x L and BCL2; the L151A mutant containing an alanine substitution at Leu151 disrupts BH3 and cannot bind BCL-x L or BCL2 (Zha et al., 1997) ; and the S112AS136AL151A triple mutant which cannot be phosphorylated and has a disrupted BH3, should not bind BCL-x L , BCL2, or 14-3-3. BCLx L immunoprecipitations using 35 S-metabolically labeled Rat1BCL-x L cells expressing dierent BAD mutants con®rmed that wild-type BAD and the S112AS136A phosphorylation mutant heterodimerized with BCL-x L , and that the L151A mutant could not co-precipitate with BCL-x L ( Figure 3a , lanes 3, 5, 7). The supernatants from these immunoprecipitations were then incubated with BAD antibody to examine the remaining BAD after BCL-x L immunoprecipitations. As expected, both wild-type and unphosphorylated BADS112AS136A co-immunoprecipitated BCLx L (Figure 3a, lanes 4, 8) . The BH3 mutant L151A did not co-precipitate BCL-x L , instead 14-3-3 was coprecipitated ( Figure 3a , lane 6), presumably by phosphorylated BADL151A. The S112AS136AL151A triple mutant also did not bind BCL-x L (Figure 3a , lanes 9, 10), indicating that the primary determinant of BAD binding to BCL-x L is the BH3 domain of BAD, not the phosphorylation state. Immuno¯uorescence staining of BAD (Figure 3b) showed that unphosphorylated BAD, which can bind BCL-x L , localized to the mitochondria. However, the non-binding triple mutant also localized to the mitochondria. Thus, subcellular localization of BAD is dictated by phosphorylation state, not by BCL-x L binding. The L151A BH3 mutant which can not bind BCL-x L or BCL2, has a higher phosphorylated fraction which binds 14-3-3 ( Figure 3a , lane 6), and can be cytosolic. The subcellular localization of BADL151A was variably mitochondrial or cytosolic (Figure 3b ), likely due to dierences in level of expression and degree of phosphorylation.
Rat1BCL-x L cells expressing wild-type or mutant BAD were cultured in media containing 0.1% FCS for 48 h and analysed for BrdU incorporation ( Figure  3c ). Consistent with our previous results, Rat1BCL-x L cells expressing wild-type BAD continued to traverse S phase with 18% of the cells incorporating BrdU after 48 h of low serum, compared to 4% BrdU positive vector-alone cells. Twelve per cent of the cells expressing the phosphorylation defective mutant BADS112AS136A incorporated BrdU in serum starvation, also exhibiting persistent cell cycle progression. Escape from cell cycle arrest caused by the phosphorylation defective mutant and wild-type BAD are similar, i.e. 60% (12% S in 0.05% serum compared to 20% in 10% serum for the phosphorylation mutant, and 18% S in 0.05% serum compared to 26% S in 10% serum for wild-type), corresponding to roughly equivalent amounts of BAD/BCL-x L heterodimers in the two cell lines. Neither the L151A BH3 mutant nor the triple mutant incorporated BrdU in low serum. These mutation analyses demonstrated that the cell cycle eect of BAD did not correlate with the phosphorylation state or mitochondrial localization, but that the ability of BAD to cause continued S phase entry strictly co-segregated with BCL-x L binding.
The cell cycle activity of BAD requires heterodimerization
To further address whether BAD must heterodimerize with BCL-x L to exert its cell cycle eect, we examined the response of bclx 7/7 mouse embryo ®broblasts (MEFs) expressing BAD to low serum. Early passage MEFs prepared from embryos of bclx +/7 x bclx +/7 matings were infected with recombinant retroviruses containing pBabeBAD and pBabeBAD mutants. Infected MEFs were used for cell cycle experiments immediately after puromycin selection. Wild-type MEFs and bclx 7/7 MEFs expressing wildtype BAD were plated in duplicate in 10% FCS. After seeding overnight, one plate was pulsed labeled with BrdU, while the other plate was cultured in 0.1% FCS for 30 ± 48 h, and then pulse labeled with BrdU ( Figure  4a ). Asynchronously growing cultures of these MEFs in 10% FCS typically had 15 ± 30% BrdU positive cells. Bclx +/+ and bclx 7/7 MEFs arrested in G0/G1 equally eciently when serum starved, indicating that the inability of BAD expressing cells to arrest was not simply due to the inactivation of BCL-x L by BAD. Similar to our ®ndings with Rat1 cells, BrdU analysis embryos. These data showed that in the absence of BCL-x L expression, BAD could not exert its cell cycle eect, suggesting that the presence of the BCL-x L /BAD heterodimer, rather than the lack of functional BCL-x L , is responsible for continued cell cycle progression in low serum.
BCL-x L is the predominant binding partner of BAD, but BAD also binds BCL2, which is present in bclx
MEFs. It is possible that the BAD/BCL2 heterodimer can function in cell cycle. Immunoprecipitations of BAD followed by Western blotting (Figure 4b ) showed that in Bclx +/+ MEFs, wild-type BAD complexed with BCL-x L , but no detectable BCL2 co-precipitated with BAD. The constitutively unphosphorylated mutant BADS112A-S136A, which has a strong cell cycle eect, was capable of binding BCL2 in addition to BCL-x L , while the presence of the L151A BH3 mutation abolished binding to either. In Bclx 7/7 MEFs, the unphosphorylated BAD mutant associated with BCL2. However, no cell cycle eect could be detected in bclx 7/7 MEFs expressing any BAD construct, even though BAD/BCL2 heterodimers were present. A direct Western blot of the Bclx +/+ and bclx 7/7 MEFs expressing wild-type and mutant BAD constructs showed similar amounts of BCL2 in all of the cultures ( Figure 4c) ; therefore, the lack of cell cycle eects in bclx 7/7 MEFs expressing BAD can not be explained by dierences in BCL2 expression. Since BAD binds to BCL-x L more strongly than to BCL2, it is likely that for the same level of BAD expression, there are more BAD/BCL-x L heterodimers than BAD/BCL2 heterodimers. This quantitative dierence could explain the lack of a cell cycle eect of BAD expression in cells with endogenous BCL2.
Unphosphorylated, mitochondrially localized BAD is unable to cause cell cycle progression in the absence of BCL-x L binding
Unphosphorylated BAD binds BCL-x L and is mitochondrial in wild-type cells. To address whether the lack of a cell cycle eect of BAD in bclx 7/7 cells is due to the lack of BAD/BCL-x L heterodimers or due to inability of BAD to target to mitochondria in the absence of BCL-x L , dual color immuno¯uorescence staining was performed on MEFs expressing wild-type and mutant BAD (Figure 5a ). In Bclx +/+ MEFs overexpressing wild-type BAD, anti-BAD antibody visualized with Cy3 (red)¯uorochrome revealed both a punctate pattern that overlaps with anti-BCL-x L staining visualized with Alexa488 (green), and a diuse cytosolic pattern. The organellar species represented active unphosphorylated BAD bound to BCL-x L , and the cytosolic staining resulted from phosphorylated BAD bound to 14-3-3. The constitutively unphosphorylated S112AS136A mutant exerted a cell cycle eect, and its staining pattern completely overlapped that of BCL-x L .
The triple mutant which was constitutively unphosphorylated, but which could not bind BCL-x L and had no cell cycle eect, was also completely organellar. Thus, simply being localized to the mitochondria did not enable BAD to exert a cell cycle eect. In bclx 7/7 cells simultaneously stained with anti-BAD antibody (green) and mitotracker (red), the pattern of wild-type BAD staining was remarkably more diuse compared to that in Bclx +/+ cells, and did not superimpose with mitochondrial staining (Figure 5b ). The cytosolic localization was presumably due to increased phosphorylation in the absence of BCL-x L binding. Both of the constitutively unphosphorylated mutants, S112AS136A and S112AS136AL151A, exhibited an immuno¯uorescence pattern completely superimposable with that of mitotracker staining (Figure 5b ). Therefore, unphosphorylated BAD was able to target to the mitochondria in the absence of BCL-x L , but was unable to exert a cell cycle eect. These experiments using BAD mutants in bclx knockout cells demonstrated that the ability of BAD to overcome G0/G1 arrest is mediated by heterodimerization with BCL-x L , not by mitochondrial localization.
BAD is not required for G0/G1 arrest
Since excess BAD/BCL-x L heterodimers induced continuous S phase progression in conditions which normally caused G0/G1 arrest, we asked whether BAD deletion would have an eect on cell cycle arrest. Early passage Bad
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MEFs derived from littermate embryos were plated in media containing 10% FCS, then switched to media with 0.1% FCS, and assayed by BrdU/PI staining and FACS analysis at 12 h intervals up to 48 h. Wild-type, heterozygous, and homozygous knockout MEFs behaved similarly in 10% FCS, and arrested in G0/ G1 approximately 24 h after culturing in low serum (data not shown), indicating that BAD expression is not necessary for normal G0/G1 arrest in response to serum deprivation. Thus, neither BAD nor BCL-x L deletion aects cell cycle arrest induced by growth factor deprivation, but excess BAD/BCL-x L heterodimers can overcome a G0/G1 checkpoint.
BAD/BCL-x L induced S phase progression is accompanied by cdk2 activation
Normal G1/S transition is accompanied by activation of the cyclin-dependent kinases (cdks) cyclin D/cdk4 and cyclin E/cdk2, leading to phosphorylation of Rb and release of E2F. To con®rm that the continued BrdU incorporation by BAD expressing cells in serum starvation represented cell cycle progression, cdk2
Oncogene BAD/BCL-x L heterodimers prevent G0/G1 arrest A Chattopadhyay et al activity in cells grown in 10% FCS and cells cultured in 0.1% FCS were compared (Figure 6 ). Whereas cdk2 activity was easily detected in Rat1 and Rat1BCL-x control cultures grown in 10% FCS, it was absent after cultures had been in 0.1% FRCS for 48 h and had arrested in G0/G1. However, the levels of cdk2 activity in Rat1BCL-x/BAD cells serum starved for 48 and 72 h were 50% of the level in cultures grown in 10% FCS. This level of cdk activity correlates with the per cent of S phase cells in 0.1% FCS, which is approximately 50% of the number of S phase cells in full serum. Similarly, in MEFs expressing BAD, cdk2 activity persisted after 48 h of 0.1% FCS (data not shown). The presence of cdk2 activity in serum starved BAD expressing cells indicated that at least one important component of the cell cycle machinery mediating normal G1 to S transition was active, consistent with BAD promoting continued cell cycle progression. In Rat1 ®broblasts, serum starvation is a cell cycle arrest signal, not an apoptotic stimulus. BAD expression in the presence of BCL-x L did not lead to signi®cant cell death in serum starved Rat1 cells, therefore, it is unlikely that the persistent cdk activity resulted from apoptosis. Instead, it suggested that cells expressing BAD bypassed the G0/G1 arrest stimulus and continued to traverse the cell cycle utilizing a pathway involving cdk2.
Discussion
Regulation of apoptosis and cell cycle control are both important to oncogenesis and vital to normal homeostasis. Disruption of cell cycle regulation can result in apoptosis and demise of the organism (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) . Conversely, inability to execute cell death correctly can lead to a cancerous phenotype with abnormal cell cycle kinetics (Donehower et al., 1992; Jacks et al., 1994) . The major class of mammalian regulator of apoptosis, the BCL2 family, have physiologic roles in both cell survival and cell cycle regulation (Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996; Huang et al., 1997; GilGomez et al., 1998; Vairo et al., 2000; Lind et al., 1999) . BCL2 and BCL-x L delay cell cycle re-entry, and BAX can accelerate entry into S phase. We used the cell death gene BAD to probe the potential relationship between apoptosis and cell cycle in ®broblasts. Our experiments revealed a hitherto unreported eect of BAD expression, that of failure to cell cycle arrest. The ability of BAD to cause continued cell cycle progression in serum starvation or contact inhibition conditions is distinct from the previously published cell cycle activity of BAX, which is accelerated progression to S phase upon proliferative stimulation (Brady et al., 1996; Gil-Gomez et al., 1998) . Overexpression of BAX has not been reported to cause abnormalities of cell cycle arrest, nor have we observed a consistent eect of BAX in serum starvation-induced cell cycle block. The use of Rat1 cells, in which cell cycle arrest signals can be separated from cell death signals, allowed us to examine cell cycle eects without confounding cell death eects. The ability of BAD/BCL-x L heterodimers to push cells into S phase without causing signi®cant apoptosis suggested that the function of BAD may not merely be to passively inactivate BCL-x L or BCL2, but that BAD may be actively involved in cell cycle control. Results from inducible expression of BAD con®rmed that the observed S phase progression was directly due to BAD, and not caused by indirect eects of selection pressures on cultures expressing apoptotic genes.
Cells en route to apoptosis can exhibit events similar to early G1 events. These include activation of immediate early genes such as Fos, Jun, and Myc, induction of cdc2, and even
3
[H]-thymidine uptake and BrdU incorporation (Pandey and Wang, 1995) . However, these events occur within 3 ± 6 h after the induction of cell death of a synchronized population of cells, much earlier than the expected time of normal G1/S transition. The result is abortive cell cycle and cell death before S phase can be traversed. Our Rat1 cultures were serum starved or density arrested for many days without signi®cant apoptosis, yet we could document DNA synthesis and traverse of S phase by BrdU incorporation, arguing that the phenotype we see re¯ects cell cycle progression, rather than early apoptotic events. In serum starved BAD-expressing cells, cdk activity was proportional to the percentage of cells in S phase, and persisted for at least 72 h during exposure to a cell cycle arrest stimulus. Detection of a cyclin-dependent kinase activity normally active in G1 to S progression lent further support that BAD expression led to failure of cell cycle arrest. Cdk2 activation occurs in apoptosis, and cdk2 activity increases in BAX-induced cell death (Hakem et al., 1999; Gil-Gomez et al., 1998) . However, in thymocytes and in the case of BAX, cdk2 activation was not associated with cell cycle progression; instead it was proposed that cdk2 had a distinct pro-apoptotic function. The timing and the lack of signi®cant apoptosis in our experiments suggest that the cdk2 activity we measured in BAD expressing cells is indicative of the activity of ongoing cell cycle machinery.
Paradoxically, the cell cycle activity of BAD absolutely requires binding to BCL-x L , just as the pro-apoptotic activity of BAD is dependent on heterodimerization with BCL-x L . To bind BCL-x L or BCL2, BAD must be dephosphorylated. Our data Figure 6 Cells expressing BAD and BCL-x L exhibit continued cdk2 activation in serum starvation. Cdk2 immunoprecipitates using M-2 antibody (Santa Cruz) from control cells (Rat1), cells overexpressing BCL-x L (BCL-x L ), and cells co-expressing BCL-x L and BAD (BCL-x L /BAD) cultured in 10% FCS or 0.1% FCS for 48 or 72 h were assayed for kinase activity in vitro using GSTpRB as substrate. Phosphorylation of GST-pRB was quantitated using an Instant Imager (Packard) before autoradiography (top panel). Eciency of cdk2 immunoprecipitation was con®rmed in all samples by Western blotting for cdk2 using M-2 goat antibody (bottom panel)
Oncogene BAD/BCL-x L heterodimers prevent G0/G1 arrest A Chattopadhyay et al using combined BH3 and phosphorylation mutations indicated that the cell cycle eect of BAD was mediated by binding to BCL-x L , not dephosphorylation. Targeting to the mitochondria was insucient for BAD to exert a cell cycle eect if binding to BCL-x L was disrupted. It would appear that the reason for BAD to translocate to the mitochondria is to bind BCL-x L or BCL2. It is interesting that the triple mutant S112AS136AL151A was localized to the mitochondria, suggesting that molecules other than BCL-x L or BCL2 may be responsible for docking BAD to mitochondria, where it can then bind BCL-x L or BCL2.
Dephosphorylated BAD binds BCL-x L and is more potent as a pro-apoptotic molecule, but the cell cycle phenotype we observed is not signi®cantly dierent between cells expressing wild-type or constitutively dephosphorylated BAD. The quantity of cells escaping G0/G1 arrest in serum starvation was usually 50 ± 60% of S phase cells in full serum regardless of the phosphorylation status of BAD, as long as it was binding to BCL-x L . This may be explained by unequal expression of wild-type and mutant BAD, or more likely, by the necessity of a certain amount of heterodimer to confer the cell cycle eect, beyond which it does not matter if more dimers are present. One potential issue is whether serum starvation would lead to BAD dephosphorylation. We did not observe increased dephosphorylated BAD when cells were cultured in low serum. We found that the eect of BAD was also present in contact inhibition, another stimulus for G0/G1 arrest.
The pro-apoptotic activity of BAD results from inactivating BCL-x L and BCL2, therefore the apoptotic phenotype of BAD overexpression would be expected to be similar to that of bclx 7/7 or bcl2 7/7 cells. However, the cell cycle activity of BAD is not simply the result of inactivating BCL-x L , because bclx
7/7
MEFs cell cycle arrest normally. Instead, normal cell cycle arrest of bclx 7/7 cells expressing BAD is strong evidence that BAD must heterodimerize to cause failure to G0/G1 arrest. BAD preferentially heterodimerizes with BCL-x L , and higher BAD expression is required to achieve the same degree of heterodimerization with BCL2. In bclx 7/7 cells, the amount of BAD/ BCL2 heterodimers is probably insucient to cause continued cell cycle progression in low serum. The lack of a cell cycle arrest phenotype in bclx 7/7 or bad
MEFs suggests that BAD/BCL-x L heterodimer has a function in cell cycle control which is dierent from inactivation of BCL-x L or BCL2. Although neither BAD nor BCL-x L is required for G0/G1 arrest, excess BAD/BCL-x L heterodimers can overcome the G0/G1 checkpoint. Since BCL-x L and BCL2 have well documented cell cycle activities, it is possible that the ratio of free BCLx L to BAD/BCL-x L may be important in regulating cell cycle arrest. Our data using Rat1 ®broblasts in which almost all of BCL-x L exist as heterodimers (Figure 1a) suggest that BAD/BCL-x L is responsible for bypass of G0/G1 arrest. We can not rule out the possibility that the presence of high amounts of free BCL-x L could counter this eect. In light of our ®nding that the amount of BAD/BCL-x L heterodimers was not dramatically increased when BAD was induced signi®cantly in the R12BAD2-4 cell line (Figure 2a) , it is also possible that the amount of free BAD may aect cell cycle arrest. Normal cell cycle arrest in bclx
MEFs expressing BAD indicated that bypass of G0/G1 arrest was not caused by BAD alone. Rather, our data are consistent with the hypothesis that the eect on cell cycle arrest requires a threshold level of BAD/BCL-x L dimers, which is not reached by endogenous heterodimers.
The molecular target of BAD/BCL-x L in cell cycle arrest remains to be elucidated. Elevated expression of the cdk inhibitor p27 has been observed in cells overexpressing BCL2 (Linette et al., 1996; Brady et al., 1996) , and increasing the level of p130/E2F4 complexes inhibiting E2F expression has been implicated as a mechanism for BCL2 to retard cell cycle entry (Lind et al., 1999; Vairo et al., 2000) . Cdk2 activation was also delayed in BCL2 expressing lymphocytes, coinciding with delayed cell cycle entry (Vairo et al., 2000) . Consistent with these reports, our data suggest that the presence of BAD/BCL-x L heterodimers prevents downregulation of cdk2 activity, resulting in inability to cell cycle arrest. It is attractive to hypothesize that if BCL2 overexpression increases p27 levels, which in turn decreases cdk2 activity, then BAD expression would cause decreased p27 levels and increased cdk2 activity, simply by opposing the activity of BCL2 or BCL-x L . Indeed, p27 levels were decreased in our cells expressing BAD/BCL-x L (data not shown), but it is dicult to determine whether a reduced p27 level is the cause or the result of continued cell cycle progression. The cell cycle mechanism of the BCL2 family may involve complex regulation of both inhibitors and activators of key cell cycle mediators.
Studies of cell cycle activities of BCL2, BCL-x L , and BAD raise intriguing questions as to the role of mitochondria in cell cycle progression. It is possible that the observed cell cycle eects all result from cellular variations in energy production controlled by mitochondrial function. However, the complexities of the mechanisms by which the BCL2 family regulate apoptosis suggest that these mitochondrial molecules could be involved in speci®c biochemical events in cell cycle regulation.
Materials and methods
Cell culture
Rat1 ®broblasts were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), penicillin/streptomycin, and L-glutamine. Cells were transfected using lipofectamine (Gibco-BRL), according to manufacturer's suggestions, with pSFFV containing BCLx L cDNA and selected with 1 mg/ml G418 or co-transfected with pSFFV containing mouse BAD cDNA and pGKHygro and selected with 0.3 mg/ml hygromycin. For retroviral infections, cDNAs encoding mouse BAD or BAD mutants were cloned in the retroviral vector pBabepuro. Viruses were produced in BOSC packaging cells (Pear et al., 1993) , and infected cells were selected with puromycin at 4 mg/ml. R12BAD2-4 was constructed by co-transfecting R12, a Rat1 cell line expressing the tetracycline transactivator, with pUHD10.3 containing BAD cDNA and pGKHygro by lipofection, and selecting for single cell clones (Gossen and Bujard, 1992) . To obtain primary bclx 7/7 ®broblasts (MEFs), embryos from bclx +/7 x bclx +/7 matings were harvested at 12 days (performed in the laboratory of Dr Kevin Roth at Washington University). For bad 7/7 MEFs, 13.5 ± 14.5 day embryos from bad +/7 x bad +/7 mice (kindly provided by Dr Stanley Korsmeyer, Dana Farber Cancer Institute) were harvested. Wild-type, heterozygous, and knockout MEFs were seeded in 60 mm dishes and infected 24 h later with high titer retroviral supernatant four times at 2 h intervals.
Cell cycle analysis
For cell cycle pro®les, cells were plated in 6-well dishes. For serum starvation experiments, cells were washed twice with PBS the next day and incubated with medium containing 0.1% serum. For contact inhibition, cells were allowed to reach con¯uence and remain con¯uent for at least 48 h. At indicated times, cells were trypsinized, centrifuged, and resuspended in Krishan's reagent (Krishan, 1975) containing 0.1 mg/ml propidium iodide (Sigma), 0.02 mg/ml RnaseA, 0.3% NP-40, and 0.1% Na Citrate. DNA content was measured with a FACSCalibur instrument (Becton-Dickinson), and data were analysed using Cell Quest and Mod®t software programs (Becton-Dickinson). For BrdU pulse labeling/propidium iodide staining experiments, cells were cultured as above, but in 100 mm dishes. At indicated times, cells were pulsed with 20 mM BrdU (Sigma) for 40 min, trypsinized, and ®xed by drop-wise addition of cold 70% ethanol. 4 N HCl was added to the ®xed cells for 30 min, neutralized by 0.1 M Borax, and washed once with PBS containing 0.5% BSA. Cells were then incubated with antiBrdU antibody (Clone B, Sigma) at 1 : 200 dilution for 30 min at room temperature, washed with PBS-BSA, then incubated with FITC-conjugated anti-mouse secondary antibody (Sigma) at 1 : 50 dilution. All antibodies were diluted in PBS containing 0.5% BSA and 0.5% Tween-20. Finally, cells were incubated in PBS containing 50 mg/ml of propidium iodide and 20 mg RNAse A for 30 min and analysed by FACS. S] label (ICN) for 12 ± 14 h. Cells were lysed in buer containing 142.5 mM KCl, 2.5 mM MgCl 2 , 1 mM HEPES, and 0.25% NP-40 for 30 min. Lysates were pre-cleared with protein A or protein G-sepharose beads, then incubated with anti-BCL-x L antibody 7B2.5 or 13.6 (kindly provided by Lawrence Boise) or anti-BAD antibody 10929 (kindly provided by Stanley Korsmeyer) at 48, followed by incubation with protein A or protein G-sepharose beads. Immunoprecipitates were boiled in Laemmli buer and separated by 12.5% SDS ± PAGE. Gels were treated for uorography and visualized by autoradiography. For coimmunoprecipitation of non-labeled proteins, 500 mg of total lysate was used. Immunoprecipitated proteins fractionated by SDS ± PAGE were transferred to PVDF membrane (Bio-
Immunoprecipitations and Western blots
